These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 36754222)
1. Inflammatory process and oxidative/nitrative stress: in vivo study in mucopolysaccharidosis type IV A patients under long-term enzyme replacement therapy. Aguilar Delgado C; Hammerschmidt T; Faverzini JL; Lopes F; Giugliani R; Baldo G; Vargas CR Arch Biochem Biophys; 2023 Mar; 737():109541. PubMed ID: 36754222 [TBL] [Abstract][Full Text] [Related]
2. Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy. Donida B; Marchetti DP; Biancini GB; Deon M; Manini PR; da Rosa HT; Moura DJ; Saffi J; Bender F; Burin MG; Coitinho AS; Giugliani R; Vargas CR Biochim Biophys Acta; 2015 May; 1852(5):1012-9. PubMed ID: 25701642 [TBL] [Abstract][Full Text] [Related]
3. Oxidative and nitrative stress and pro-inflammatory cytokines in Mucopolysaccharidosis type II patients: effect of long-term enzyme replacement therapy and relation with glycosaminoglycan accumulation. Jacques CE; Donida B; Mescka CP; Rodrigues DG; Marchetti DP; Bitencourt FH; Burin MG; de Souza CF; Giugliani R; Vargas CR Biochim Biophys Acta; 2016 Sep; 1862(9):1608-16. PubMed ID: 27251652 [TBL] [Abstract][Full Text] [Related]
5. Oxidative profile exhibited by Mucopolysaccharidosis type IVA patients at diagnosis: Increased keratan urinary levels. Donida B; Marchetti DP; Jacques CED; Ribas G; Deon M; Manini P; da Rosa HT; Moura DJ; Saffi J; Giugliani R; Vargas CR Mol Genet Metab Rep; 2017 Jun; 11():46-53. PubMed ID: 28487826 [TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice. Dvorak-Ewell M; Wendt D; Hague C; Christianson T; Koppaka V; Crippen D; Kakkis E; Vellard M PLoS One; 2010 Aug; 5(8):e12194. PubMed ID: 20808938 [TBL] [Abstract][Full Text] [Related]
7. Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA. Peracha H; Sawamoto K; Averill L; Kecskemethy H; Theroux M; Thacker M; Nagao K; Pizarro C; Mackenzie W; Kobayashi H; Yamaguchi S; Suzuki Y; Orii K; Orii T; Fukao T; Tomatsu S Mol Genet Metab; 2018 Sep; 125(1-2):18-37. PubMed ID: 29779902 [TBL] [Abstract][Full Text] [Related]
9. Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome. Tomatsu S; Sawamoto K; Alméciga-Díaz CJ; Shimada T; Bober MB; Chinen Y; Yabe H; Montaño AM; Giugliani R; Kubaski F; Yasuda E; Rodríguez-López A; Espejo-Mojica AJ; Sánchez OF; Mason RW; Barrera LA; Mackenzie WG; Orii T Drug Des Devel Ther; 2015; 9():1937-53. PubMed ID: 25897204 [TBL] [Abstract][Full Text] [Related]
10. [Analysis of GALNS gene mutation in thirty-eight Chinese patients with mucopolysaccharidosis type IVA]. Ye J; Lei HL; Zhang HW; Qiu WJ; Han LS; Wang Y; Li XY; Gu XF Zhonghua Er Ke Za Zhi; 2013 Jun; 51(6):414-9. PubMed ID: 24120057 [TBL] [Abstract][Full Text] [Related]
11. The youngest pair of siblings with Mucopolysaccharidosis type IVA to receive enzyme replacement therapy to date: A case report. Frigeni M; Rodriguez-Buritica DF; Saavedra H; Gunther KA; Hillman PR; Balaguru D; Northrup H Am J Med Genet A; 2021 Nov; 185(11):3510-3516. PubMed ID: 34472180 [TBL] [Abstract][Full Text] [Related]
12. Plasma Proteomic Analysis in Morquio A Disease. Álvarez JV; Bravo SB; Chantada-Vázquez MP; Barbosa-Gouveia S; Colón C; López-Suarez O; Tomatsu S; Otero-Espinar FJ; Couce ML Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34200496 [TBL] [Abstract][Full Text] [Related]
14. Efficient CRISPR/Cas9 nickase-mediated genome editing in an in vitro model of mucopolysaccharidosis IVA. Leal AF; Alméciga-Díaz CJ Gene Ther; 2023 Feb; 30(1-2):107-114. PubMed ID: 35581402 [TBL] [Abstract][Full Text] [Related]
15. Elosulfase alfa: first global approval. Sanford M; Lo JH Drugs; 2014 Apr; 74(6):713-8. PubMed ID: 24700469 [TBL] [Abstract][Full Text] [Related]
16. Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme replacement therapy. Pal AR; Mercer J; Jones SA; Bruce IA; Bigger BW PLoS One; 2018; 13(9):e0203216. PubMed ID: 30226843 [TBL] [Abstract][Full Text] [Related]
17. Elosulfase Alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio A syndrome). Lyseng-Williamson KA BioDrugs; 2014 Oct; 28(5):465-75. PubMed ID: 25200032 [TBL] [Abstract][Full Text] [Related]
19. A Case Report of a Japanese Boy with Morquio A Syndrome: Effects of Enzyme Replacement Therapy Initiated at the Age of 24 Months. Nakamura-Utsunomiya A; Nakamae T; Kagawa R; Karakawa S; Sakata S; Sakura F; Tani C; Matsubara Y; Ishino T; Tajima G; Okada S Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32024277 [TBL] [Abstract][Full Text] [Related]
20. Characterization of New Proteomic Biomarker Candidates in Mucopolysaccharidosis Type IVA. Álvarez VJ; Bravo SB; Chantada-Vazquez MP; Colón C; De Castro MJ; Morales M; Vitoria I; Tomatsu S; Otero-Espinar FJ; Couce ML Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379360 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]